Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Forte Biosciences (FBRX) today and set a price target of $70.00. The company’s shares closed last Monday at $34.92.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 12.5% and a 33.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Forte Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $85.00.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient’s immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
